CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02292225
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:17.995649+00:00
Published At: 2023-02-27T00:00:00+00:00
Record Updated At: 2023-02-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphocytic Leukemia, Chronic", "Lymphoma, Small Lymphocytic"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-02-27"
protocolSection.identificationModule.nctId: "NCT02292225"
protocolSection.identificationModule.officialTitle: "A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton\u0027s Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.